Cardiac amyloidosis is a rare disease in which abnormal proteins accumulate in the heart, often leading to heart failure. Diagnosing the condition can be difficult, but a new imaging approach may offer a more reliable option. According to a report from Medical Xpress, a recent clinical trial published in JAMA found that a PET/CT radiotracer demonstrated high sensitivity and specificity for diagnosing the disease.
The trial results suggest the imaging agent could improve diagnostic accuracy, potentially enabling earlier detection and treatment. The report does not include independent comparisons or additional sources, so the findings rest on the single trial as described. Still, the high sensitivity and specificity reported indicate the radiotracer may be a valuable tool for identifying cardiac amyloidosis in patients.